Hybrigenics and Servier enter into a licence and research collaboration agreement in oncology and other therapeutic fields
Hybrigenics will receive EUR four million over three years to identify new deubiquitinating enzymes and screen their inhibitors, and is further eligible to success milestones
11-Oct-2011 -
Hybrigenics and Servier announced that they have signed a licence and research collaboration agreement in the field of deubiquitinating enzymes (DUBs) applied to oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases.Hybrigenics will identify and ...
cardiovascular diseases
diabetes
enzymes
+6